Clinical trials
Glioma clinical trials
Below are recruiting glioma clinical trials, each written for real people, not researchers. We’re tracking 335 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05009992RecruitingPhase 2
Drug combination for diffuse midline gliomas in children and young adults
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
Birmingham, AlabamaAges 2–39 - NCT06333899RecruitingEarly Phase 1
Lorlatinib for newly diagnosed brain tumors with ROS or ALK fusion
This trial tests if lorlatinib, a targeted pill, can shrink or slow the growth of high-grade brain tumors that have a specific ROS or ALK genetic change. It is for children and young adults who have not yet had treatment for their tumor.
Aurora, ColoradoAges 1–21 - NCT06964737RecruitingPhase 1
CAR T-cell therapy for recurrent brain tumors
This trial tests a new type of immunotherapy called CAR T-cells that target a protein called GARP on your tumor cells. It is for people whose high-grade glioma (a fast-growing brain tumor) has come back after previous treatment.
Columbus, OhioAges 18 years+ - NCT07608003Recruiting
MRI AI model study for midline brain tumors
This study uses artificial intelligence to analyze MRI scans of midline brain tumors (gliomas) to help predict how the disease may progress and improve treatment planning. Researchers are collecting data from multiple hospitals to teach an AI system to better understand these tumors.
Changsha, HunanAges Any age - NCT05553041RecruitingEarly Phase 1
PET-MRI scan test for aggressive brain tumors in children
This early-phase study uses a special PET scan plus MRI to help doctors tell apart tumor changes in children with aggressive gliomas. It may help find whether treatment is working or if the tumor is progressing, while also mapping tumor activity in the brain.
Philadelphia, PennsylvaniaAges 1–21 - NCT05839379Recruiting
Targeted therapy study for children and young adults with brain tumors
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Aurora, ColoradoAges 1–39 - NCT05843253RecruitingPhase 2
Ribociclib plus everolimus or temozolomide for certain brain tumors
This Phase 2 study tests ribociclib with either everolimus or temozolomide, depending on the specific brain tumor type. It may help slow tumor growth in children and young adults whose tumor has specific genetic changes and who have had recent standard radiation therapy.
Aurora, ColoradoAges 1–39 - NCT07210632RecruitingEarly Phase 1
Nivolumab dye imaging in high grade glioma surgery
This trial tests if a special dye attached to the immunotherapy drug nivolumab can help surgeons see tumor cells during surgery for high grade glioma. You may join if you are scheduled for surgery and your organs are working well.
Nashville, TennesseeAges 18 years+ - NCT04166409RecruitingPhase 3
Selumetinib versus chemo for low-grade brain tumor in children
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
Birmingham, AlabamaAges 2–21 - NCT05278208RecruitingPhase 1/Phase 2
Lutathera for high-grade brain tumors that returned or got worse
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
Aurora, ColoradoAges 4–39 - NCT03101813Recruiting
Share DIPG/DMG tumor information for an international registry
This trial builds an international registry (a secure collection of patient records) for people who have been diagnosed with DIPG/DMG, including children and adults. Sharing information can help researchers better understand these tumors and plan future studies.
Cincinnati, OhioAges Any age - NCT04540107RecruitingPhase 1
MRI scan study to characterize lower-grade brain tumors
This Phase 1 study uses special MRI scans (including a form of MR spectroscopy) to better understand lower-grade gliomas. It is designed to test how well the imaging can “characterize” the tumor and to improve understanding for treatment planning.
San Francisco, CaliforniaAges 18 years+ - NCT05555550RecruitingEarly Phase 1
PET-MRI scan to study low-grade brain tumors in children
This early-phase study tests how well a special PET-MRI scan (using a radioactive tracer) can find and measure low-grade brain tumors. It may help doctors better track these tumors while you start or continue treatment.
Philadelphia, PennsylvaniaAges 1–21 - NCT06161974RecruitingPhase 2
Olutasidenib and temozolomide for IDH1-mutant high-grade glioma
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
Aurora, ColoradoAges 12–39 - NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
Basking Ridge, New JerseyAges 18 years+ - NCT07547163Recruiting
Patient feedback on low-grade brain tumor treatment
This study asks patients with a specific type of low-grade brain tumor (IDH mutant grade 2 glioma) to share their experiences and quality of life while receiving a treatment called vorasidenib, with or without radiation. Your feedback helps doctors understand how well the treatment works from your perspective.
MilanAges 18 years+ - NCT04485559RecruitingPhase 1
Trametinib and everolimus for recurrent gliomas
This trial tests two drugs, trametinib and everolimus, for children and young adults with recurrent or progressive gliomas (a type of brain tumor). The goal is to see if this drug combination is safe and effective in treating these tumors.
Birmingham, AlabamaAges 1–25 - NCT05476939RecruitingPhase 3
BIOMEDE 2.0 trial for DIPG and similar brainstem gliomas
This phase 3 study tests targeted treatments (ONC201 or everolimus) for children with DIPG or similar diffuse midline brain tumors, based on the tumor’s genetic markers. It aims to improve outcomes by matching treatment to the tumor biology and comparing approaches in a randomized way.
AarhusAges 6 months+ - NCT04196413RecruitingPhase 1
CAR T cell treatment for a specific brainstem glioma mutation
This Phase 1 study tests a custom immune therapy called GD2 CAR T cells in children and adults with a specific type of diffuse midline glioma (DMG) that has the H3K27M mutation. The goal is to see if the treatment is safe and can help control the cancer.
Stanford, CaliforniaAges 2–60 - NCT07110246RecruitingPhase 2
Dabrafenib and trametinib for BRAF-mutated low-grade gliomas
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
Birmingham, AlabamaAges 1–25 - NCT07680439RecruitingPhase 2
CAR T cell therapy study for children with DIPG brain tumor
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
Los Angeles, CaliforniaAges 1–26 - NCT07416188RecruitingPhase 1/Phase 2
LMP744 drug for returning glioblastoma
This trial tests an experimental drug called LMP744 for people whose glioblastoma has come back. It aims to see if the drug can slow or stop tumor growth by targeting specific proteins in cancer cells.
Bethesda, MarylandAges 18–99 - NCT07703761Recruiting
AI analysis of brain tumor MRI scans
This trial uses artificial intelligence to analyze MRI scans from people diagnosed with a type of brain tumor called glioma. It aims to better understand the cancer from diagnosis through treatment, which could help guide future care.
TrentoAges 18–60 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Glioma trials by city
Studies with a site in or near these metro areas.
Glioma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for glioma?
- Yes. Clin2 currently lists 335 recruiting glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.